Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

Video

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, and senior physician at Dana-Farber Cancer Institute, as well as the Jerome and Nancy Kohlberg chair and professor of medicine at Harvard Medical School, discusses the rationale for the phase 3 COSMIC-313 trial (NCT03937219) in advanced renal cell carcinoma (RCC).

The ongoing COSMIC-313 study is randomizing patients with previously untreated advanced or metastatic RCC 1:1 to the combination of ipilimumab (Yervoy), nivolumab (Opdivo), and cabozantinib (Cabometyx) or ipilimumab, nivolumab, and a cabozantinib-matched placebo, says Choueiri. The primary end point of the study is progression-free survival, with overall survival, overall response rate, safety, and quality of life serving as secondary end points.

Cabozantinib, a VEGF receptor targeting agent that can also target MET and AXL, is currently approved as a single agent for the treatment of patients with previously untreated advanced RCC, as well as for patients with relapsed/refractory disease.

Nivolumab, a PD-1 inhibitor, is approved as a single agent for patients with advanced RCC, and in combination with ipilimumab for patients with intermediate- and poor-risk advanced RCC.

Early data have shown that the triplet regimen, with cabozantinib dosed at 40 mg daily, is tolerable among this patient population, Choueiri says.

Notably, the COSMIC-313 trial is the first trial in RCC to utilize a modern control arm rather than sunitinib (Sutent), concludes Choueiri.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center